Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 211.0% in August

Posted by Brenda Bartman on Aug 27th, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 164,738 shares, a growth of 211.0% from the July 30th total of 52,977 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 206,606 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Dyadic International

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International during the 2nd quarter worth $50,000. BlackRock Inc. acquired a new stake in shares of Dyadic International during the second quarter worth $177,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Price Performance

Shares of Dyadic International stock traded down $0.03 during trading on Thursday, hitting $0.63. 171,458 shares of the company were exchanged, compared to its average volume of 179,102. The firm has a 50 day moving average price of $0.96 and a 200 day moving average price of $0.85. The stock has a market capitalization of $23.03 million, a price-to-earnings ratio of -2.75 and a beta of 1.12. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 4.08. Dyadic International has a fifty-two week low of $0.62 and a fifty-two week high of $1.60.

Dyadic International (NASDAQ:DYAI – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $0.96 million during the quarter, compared to analyst estimates of $1.02 million. Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%. On average, equities analysts expect that Dyadic International will post -0.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dyadic International has a consensus rating of “Hold” and an average target price of $3.00.

Get Our Latest Stock Report on DYAI

About Dyadic International

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.